Pulling Tavneos ignores years of real-world evidence showing that the drug supports remission, reduces relapse risk and cuts harmful glucocorticoid exposure for people with a devastating, life-threatening disease. As the only FDA-approved targeted oral treatment for severe active GPA and MPA, removing it would leave patients with no comparable alternative, to their detriment.